Early-Phase Immunotherapy Demonstrates Modest Activity in Recurrent or Metastatic Head and Neck Cancer
Clinical Summary:
- Design/Population: This retrospective analysis evaluated 158 patients with recurrent or metastatic head and neck squamous cell carcinoma enrolled in early-phase immunotherapy clinical trials. Most patients were heavily pretreated, with a median of 3 prior systemic therapies and prior exposure to immune checkpoint inhibitors.
- Key Outcomes: Early-phase immunotherapies demonstrated manageable safety and modest antitumor activity, with bispecific antibodies showing greater clinical promise than other investigational approaches. Genomic alterations, including PIK3CA, TP53, and CDKN2A/B, were associated with poorer outcomes.
- Clinical Relevance: These findings suggest that future immunotherapy strategies should prioritize biomarker-driven patient selection and mechanism-specific approaches rather than broad treatment intensification.
Harold Nathan Tan, MD, The University of Texas MD Anderson Cancer Center, Houston, Texas, discusses findings from a retrospective analysis evaluating early-phase immunotherapy trials in patients with recurrent or metastatic head and neck squamous cell carcinoma.
The analysis demonstrated manageable safety and modest clinical activity across investigational immunotherapy approaches, with bispecific antibodies showing the most encouraging antitumor activity. Dr Tan also discusses how genomic alterations associated with poorer outcomes may help guide future biomarker-driven immunotherapy strategies and improve patient selection for early-phase clinical trials.
Transcript:
Good afternoon, everyone, I’m Harold Nathan Tan, I’m an assistant professor in the department of thoracic/head and neck medical oncology here at MD Anderson.
Today, I would like to discuss our research entitled "early-phase immunotherapy trials," where we wanted to evaluate the benefit of these novel immunotherapy agents specifically for patients with head and neck cancer.
As we know, immune checkpoint inhibitors have changed the treatment landscape of recurrent and metastatic head and neck cancer. But the reality is that most patients either do not respond or eventually develop resistance. We therefore wanted to understand what happens when we move beyond conventional PD-1 blockade.
We evaluated 158 patients with recurrent or metastatic head and neck squamous cell carcinoma who received investigational immunotherapies in early-phase clinical trials at MD Anderson. This was a heavily pretreated population. Patients had received a median of 3 prior systemic therapies, and 80% had already been exposed to checkpoint inhibitors.
What we found was a mixed but very informative picture. Toxicity was generally manageable, with approximately half of patients experiencing some form of toxicity, but only 15% of patients had grade ≥3 toxicity. Nevertheless, the overall antitumor activity was modest. The objective response rate was 8%, and the clinical benefit rate was 16%. Importantly, bispecific antibodies showed a more encouraging signal than the other therapeutic classes.
We also found that genomic alterations are important in helping us determine whether patients would benefit from novel immunotherapy agents. Specifically, patients with PIK3CA mutations, TP53 mutations, and CDKN2A/B alterations were associated with worse outcomes.
Our findings suggest that the future of immunotherapy in head and neck cancer will not be about indiscriminately adding another immune agent. It will be about selecting the right mechanism for the specific immune and molecular architecture of the tumor.
Source:
Tan HN, Stephen B, Mirallas O, et al. Novel immunotherapy agents in early-phase trials for head and neck cancer. JAMA Netw Open. Published online: July 16, 2026. doi: 10.1001/jamanetworkopen.2026.23522
